AcquisitionsNov 12, 2026, 04:16 PM
Lineage Cell Therapeutics Acquires NeuroAirmid, Adds Huntington's Disease Candidate
AI Summary
Lineage Cell Therapeutics announced the acquisition of NeuroAirmid Therapeutics, adding the clinical-stage HUNT1 program for Huntington's Disease to its pipeline. The acquisition includes rights to the ongoing REGEN4HD Phase 1b/2a clinical study. Lineage also reported its third quarter 2026 financial results, showing a net income of $4.2 million, largely due to a non-cash fair value remeasurement of warrant liabilities. Additionally, the company secured a U.S. patent for its AlloSCOPE "5D" cell manufacturing technology.
Key Highlights
- Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics for $4.7M cash and equity at closing, with up to $5M due on the first anniversary and up to $48M in success-based milestones.
- The acquisition adds HUNT1, a clinical-stage neural cell therapy candidate for Huntington's Disease, to Lineage's pipeline.
- HUNT1 is currently being evaluated in the Phase 1b/2a REGEN4HD clinical study, which has dosed 6 patients to date.
- Lineage will assume responsibility for clinical development costs of the HUNT1 program post-study and future cell manufacturing.
- Lineage also reported Q3 2026 financial results, with revenues of $1.5M and a net income of $4.2M, driven by warrant liability remeasurement.
- The company announced the issuance of a U.S. patent covering its proprietary AlloSCOPE™ "5D" cell manufacturing technology.
- Lineage's cash, cash equivalents, and marketable securities as of September 30, 2026, were $45.2M, expected to support operations into Q2 2028.
Price Impact
More from LCTX